Your browser doesn't support javascript.
loading
Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy.
Walker, Jamie M; Richardson, Timothy E; Farrell, Kurt; Iida, Megan A; Foong, Chan; Shang, Ping; Attems, Johannes; Ayalon, Gai; Beach, Thomas G; Bigio, Eileen H; Budson, Andrew; Cairns, Nigel J; Corrada, María; Cortes, Etty; Dickson, Dennis W; Fischer, Peter; Flanagan, Margaret E; Franklin, Erin; Gearing, Marla; Glass, Jonathan; Hansen, Lawrence A; Haroutunian, Vahram; Hof, Patrick R; Honig, Lawrence; Kawas, Claudia; Keene, C Dirk; Kofler, Julia; Kovacs, Gabor G; Lee, Edward B; Lutz, Mirjam I; Mao, Qinwen; Masliah, Eliezer; McKee, Ann C; McMillan, Corey T; Mesulam, M Marsel; Murray, Melissa; Nelson, Peter T; Perrin, Richard; Pham, Thao; Poon, Wayne; Purohit, Dushyant P; Rissman, Robert A; Sakai, Kenji; Sano, Mary; Schneider, Julie A; Stein, Thor D; Teich, Andrew F; Trojanowski, John Q; Troncoso, Juan C; Vonsattel, Jean-Paul.
Affiliation
  • Walker JM; From the Department of Pathology, University of Texas Health Science Center, San Antonio, Texas, USA.
  • Richardson TE; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio, Texas, USA.
  • Farrell K; From the Department of Pathology, University of Texas Health Science Center, San Antonio, Texas, USA.
  • Iida MA; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio, Texas, USA.
  • Foong C; Department of Pathology, State University of New York, Upstate Medical University, Syracuse, New York, USA.
  • Shang P; Department of Pathology and Nash Family Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Attems J; Neuropathology Brain Bank & Research Core, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Ayalon G; Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Beach TG; Department of Pathology and Nash Family Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Bigio EH; Neuropathology Brain Bank & Research Core, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Budson A; Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Cairns NJ; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Corrada M; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Cortes E; Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Dickson DW; Department of Neuroscience, Genentech Inc., South San Francisco, California, USA.
  • Fischer P; Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona, USA.
  • Flanagan ME; Department of Pathology, Northwestern Cognitive Neurology and Alzheimer Disease Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Franklin E; Department of Pathology, VA Medical Center & Boston University School of Medicine, Boston, Massachusetts, USA.
  • Gearing M; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Glass J; Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, California, USA.
  • Hansen LA; Department of Pathology and Nash Family Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Haroutunian V; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
  • Hof PR; Department of Laboratory Medicine and Pathobiology, University of Toronto, Laboratory Medicine Program, University Health Network, and Tanz Centre for Research in Neurodegenerative Disease, Krembil Brain Institute, Toronto, Ontario, Canada.
  • Honig L; Department of Pathology, Northwestern Cognitive Neurology and Alzheimer Disease Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Kawas C; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Keene CD; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Kofler J; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Kovacs GG; Departments of Neurosciences and Pathology, University of California, San Diego, La Jolla, California, USA.
  • Lee EB; Department of Psychiatry and Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Lutz MI; Department of Pathology and Nash Family Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Mao Q; Neuropathology Brain Bank & Research Core, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Masliah E; Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • McKee AC; Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
  • McMillan CT; Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, California, USA.
  • Mesulam MM; Department of Pathology, University of Washington, Seattle, Washington, USA.
  • Murray M; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Nelson PT; Department of Laboratory Medicine and Pathobiology, University of Toronto, Laboratory Medicine Program, University Health Network, and Tanz Centre for Research in Neurodegenerative Disease, Krembil Brain Institute, Toronto, Ontario, Canada.
  • Perrin R; Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Pham T; Institute of Neurology, Medical University of Vienna, Vienna, Austria.
  • Poon W; Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona, USA.
  • Purohit DP; Departments of Neurosciences and Pathology, University of California, San Diego, La Jolla, California, USA.
  • Rissman RA; Department of Pathology, VA Medical Center & Boston University School of Medicine, Boston, Massachusetts, USA.
  • Sakai K; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Sano M; Department of Pathology, Northwestern Cognitive Neurology and Alzheimer Disease Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Schneider JA; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
  • Stein TD; Department of Pathology and Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.
  • Teich AF; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Trojanowski JQ; Department of Pathology, Oregon Health Sciences University, Portland, Oregon, USA.
  • Troncoso JC; Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, California, USA.
  • Vonsattel JP; Department of Pathology and Nash Family Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
J Neuropathol Exp Neurol ; 80(2): 102-111, 2021 01 20.
Article in En | MEDLINE | ID: mdl-33367843
Primary age-related tauopathy (PART) is a neurodegenerative entity defined as Alzheimer-type neurofibrillary degeneration primarily affecting the medial temporal lobe with minimal to absent amyloid-ß (Aß) plaque deposition. The extent to which PART can be differentiated pathoanatomically from Alzheimer disease (AD) is unclear. Here, we examined the regional distribution of tau pathology in a large cohort of postmortem brains (n = 914). We found an early vulnerability of the CA2 subregion of the hippocampus to neurofibrillary degeneration in PART, and semiquantitative assessment of neurofibrillary degeneration in CA2 was significantly greater than in CA1 in PART. In contrast, subjects harboring intermediate-to-high AD neuropathologic change (ADNC) displayed relative sparing of CA2 until later stages of their disease course. In addition, the CA2/CA1 ratio of neurofibrillary degeneration in PART was significantly higher than in subjects with intermediate-to-high ADNC burden. Furthermore, the distribution of tau pathology in PART diverges from the Braak NFT staging system and Braak stage does not correlate with cognitive function in PART as it does in individuals with intermediate-to-high ADNC. These findings highlight the need for a better understanding of the contribution of PART to cognitive impairment and how neurofibrillary degeneration interacts with Aß pathology in AD and PART.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Aging / Tauopathies / CA2 Region, Hippocampal / Neurons Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Neuropathol Exp Neurol Year: 2021 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Aging / Tauopathies / CA2 Region, Hippocampal / Neurons Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Neuropathol Exp Neurol Year: 2021 Document type: Article Affiliation country: Country of publication: